[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-atrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-atrophy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":48},"100544535","a-study-collecting-health-information-to-understand-and-prevent-gastric-cancer-100544535",false,"NCT06370143","A Study Collecting Health Information to Understand and Prevent Gastric Cancer","Gastric Cancer Prevention: Understanding Precursor Lesions and Risk Factors for Progression to Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Able to read and understand English and Spanish\n* Meet criteria for one of three potentially eligible study populations:\n\n  * Individuals with gastric atrophy, gastric intestinal metaplasia, or dysplasia: Had a previous diagnosis of or have been diagnosed by the investigation team with gastric atrophy, gastric intestinal metaplasia, or dysplasia of the gastric mucosa on pathology review from an endoscopic biopsy. Individuals who have a prior history of early gastric cancer may be included, if they were treated endoscopically and have no evidence of disease. Individuals who have a prior history of a cancer other than upper gastrointestinal cancer may also be included, if they have no evidence of disease for at least 1 year prior to study enrollment and are not undergoing active treatment for any malignancy at any time throughout the study period\n  * Healthy controls (average risk): Individuals with no history of cancer or gastric precursor lesions undergoing a clinically indicated endoscopy at MSK for workup or dyspepsia or reflux\n  * Gastric cancer cases: Individuals with a known diagnosis of early gastric adenocarcinoma undergoing surgical resection at MSK\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Women who are pregnant (may be enrolled after delivery)\n* Individuals with a prior history of upper gastrointestinal surgery or a prior cancer who are undergoing active treatment for malignancy or have been diagnosed within 1 year prior to the study enrollment or with pancreatic cancer. (This does not include incidentally diagnosed primary gastric adenocarcinoma identified during study follow up. Individuals diagnosed with gastric carcinoid limited to the stomach will also be included, given their ongoing parallel risk for gastric adenocarcinoma.)\n* Have severe comorbidities with expected survival time \\\u003C2 years or which would prevent them from undergoing routine elective EGD (at the discretion of the patient's provider and the study team)\n* Individuals having Hereditary Diffuse Gastric Cancer Syndrome, mutations including CDH1 and CTNNA1, or more than one genetic mutation\n* Exclude high risk esophageal and duodenal lesions including:\n\n  * Duodenal Adenoma\n  * Dysplasia or cancer at the esophagus or gastroesophageal junction\n* Patients with an increased risk for biopsies during EGD, such as those with clotting disorders.",true,"ALL","18 Years",{"count":20,"type":21},3200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to create a registry of participants with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled.",[25,26,27,28,29],"Gastric Atrophy","Gastric Intestinal Metaplasia","Dysplasia","Gastric Adenocarcinoma","Gastric Cancer",[31,32,33,26,34,35,36],"Gastric cancer","gastric adenocarcinoma","gastric atrophy","dysplasia","Memorial Sloan Kettering Cancer Center","24-083","RECRUITING","2026-01-28",{"date":40,"type":41},"2026-01-30","ACTUAL",{"date":43,"type":41},"2024-04-11",{"date":45,"type":21},"2036-04-11",{"name":35,"class":47},"OTHER",7,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100597591","gastrin-anti-helicobacter-pylori-and-pepsinogen-diagnostic-accuracy-study-100597591","NCT07060482","Gastrin, Anti-helicobacter Pylori and Pepsinogen Diagnostic Accuracy Study","Diagnostic Performance of Combined Assays for Gastrin-17, Pepsinogen and Anti-helicobacter Pylori Antibodies for Diagnosing Gastric Atrophy.","GAP-DA","Inclusion Criteria:\n\n* Patients presenting for a routine diagnostic gastroscopy.\n\nExclusion Criteria:\n\n* Patients presenting for a therapeutic procedure such as dilations or stenting.",{"count":58,"type":21},240,"This research study is taking place to find out if a simple blood test can diagnose inflammation in the stomach. Prolonged inflammation in the stomach can lead to Ulcers and even Cancer in the long run.\n\nCurrently, a camera test is needed to identify inflammation in the stomach. The method being tested in this study may be able to do this using just a pinprick of blood.\n\nIf this test proves to be good at diagnosing inflammation in the stomach with just a pinprick of blood, it may be used in the future to decide who actually needs to have a full camera test done or not. This could really improve the waiting lists for these camera tests in the future. It may also mean that we can identify problems at an earlier stage.",[25],[33,62,63,64,65],"pepsinogen","gastrin 17","anti-helicobacter pylori antibodies","gastroscopy","NOT_YET_RECRUITING","2025-07-01",{"date":69,"type":41},"2025-07-11",{"date":71,"type":21},"2025-08-01",{"date":73,"type":21},"2026-02-01",{"name":75,"class":47},"Royal College of Surgeons, Ireland",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100304969","surveillance-of-patients-with-precancerous-lesions-of-the-stomach-100304969","NCT03250091","Surveillance of Patients With Precancerous Lesions of the Stomach","Surveillance Strategies of Patients With Precancerous Conditions and Lesions in the Stomach","Inclusion Criteria:\n\nPatients undergoing upper endoscopy Motivation to participate in the study Signed consent\n\nExclusion Criteria:\n\nKnown gastric cancer Unwillingness or inability to co-operate",{"count":84,"type":21},2000,"The project will aim to identify and determine subgroups of patients with different risks of progression to gastric cancer and to assess appropriate follow-up intervals. Implementing risk stratification only high risk individuals will be offered and performed endoscopic surveillance.",[29,26,25,87],"Gastric Dysplasia",[89,90,91,33,92],"gastric precancerous lesions","gastric cancer","gastric intestinal Metaplasia","gastric dysplasia","2018-08-20",{"date":95,"type":41},"2018-08-21",{"date":97,"type":41},"2017-06-19",{"date":99,"type":21},"2027-12",{"name":101,"class":47},"University of Latvia",1]